



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 12, 2023

The General Manager BSE Limited Corporate Relation Department Phiroze Jeejeeboy Towers 14 th Floor, Dalal Street, Fort, Mumbai- 400 001 Scrip Code: 524816	National Stock Exchange of India Limited Listing Department Exchange Plaza Bandra Kurla Complex Bandra (East) Mumbai 400 051 Scrip Code: NATCOPHARM
--	---

Dear Sir/Ma'am,

Sub: Intimation of closure of buyback of equity shares by Natco Pharma Limited through open market in terms of the provisions of the Companies Act, 2013 and its rules, as amended and SEBI (Buy-back of Securities) Regulations, 2018, as amended (“Buyback Regulations”)

This is in furtherance to, (i) our intimation letter dated March 2, 2023, regarding convening of meeting of our board of directors of the Company ("**Board**") to approve the Buyback (as defined hereinafter), (ii) our letter dated March 8, 2023, informing the outcome of the meeting of our Board where the buyback of our equity shares via the "Open Market" route through the stock exchanges mechanism was approved and (iii) our letter dated March 10, 2023, regarding the submission of public announcement dated March 9, 2023 ("**Public Announcement**").

Pursuant to the resolution passed by the Board at its meeting held on March 8, 2023, the Company was authorized to buyback its fully paid-up equity shares of face value of Rs. 2/- (Rupees Two only) each ("**Equity Shares**") at a price not exceeding Rs. 700/- (Rupees Seven Hundred only) per Equity Share (the "**Maximum Buyback Price**") payable in cash for an aggregate amount not exceeding Rs. 210,00,00,000/- (Rupees Two Hundred and Ten Crores only) (the "**Maximum Buyback Size**"), from the shareholders of the Company excluding promoters, promoter group and persons who are in control of the Company, via the "Open Market" route through the stock exchanges mechanism, i.e., using the electronic trading facilities of the stock exchanges where the Equity Shares of the Company are listed (i.e., **BSE Limited and National Stock Exchange of India Limited**), in accordance with the provisions of Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended ("**Buyback Regulations**") and the Companies Act, 2013 (including the rules and regulations framed thereunder), as amended, and other applicable provisions (the process hereinafter referred to as the "**Buyback**").

The Maximum Buyback Size did not include any expenses incurred or to be incurred for the Buyback like filing fees payable to SEBI, advisors' fees, stock exchange fees, brokerage, costs, fees, turnover charges, applicable taxes including inter alia securities transaction tax, goods and services tax, stamp duty, etc., public announcement publication expenses and other incidental and related expenses ("**Transaction Costs**").



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

The Buyback commenced on March 21, 2023 in accordance with the provisions of Buyback regulations. In this regard, please be informed that the Company has as on May 12, 2023 bought back 34,47,295 (Thirty Four Lakhs Forty Seven Thousand Two Hundred and Ninety Five) Equity Shares at an average price of Rs. 609.1712 (Rupees Six Hundred Nine and paisa One Seven One Two only) per Equity Share for an aggregate consideration of Rs. 209,99,92,885.33 (Rupees Two Hundred and Nine Crores Ninety Nine Lakhs Ninety Two Thousand Eight Hundred Eighty Five and paisa Three Three only) which represents 100.00% of the Maximum Buyback Size. Accordingly, the Buyback Committee hereby approves the closure of Buyback pursuant to the terms of the Public Announcement, with effect from the closing of trading hours of May 12, 2023, prior to the six months from the date of commencement of the Buyback.

The summary of the pre and post Buyback shareholding pattern of the Company is enclosed as **Annexure - I**.

This is for your information and records and may be treated as compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All capitalised terms not defined herein shall have the same meaning, as specified in the Public Announcement.

For Natco Pharma Limited

CH. Venkat Ramesh
Company Secretary &
Compliance Officer

Place: Hyderabad
Date: May 12, 2023



Annexure I

Shareholding pattern of the Company Pre Buyback and post Buyback, is given below:

Category	Pre-Buyback*		Post Buyback	
	No. of Equity Shares	%	No. of Equity Shares	%
(A) Promoter & Promoter Group	8,91,20,575	48.82	8,91,20,575	49.76
(B) Public	9,34,36,590	51.18	8,99,89,295	50.24
(C1) Shares underlying DRs	-	-	-	-
(C2) Shares held by Employee Trust	-	-	-	-
(C) Non-Promoter-Non Public (C1+C2)	-	-	-	-
Total (A+B+C)	18,25,57,165	100.00	17,91,09,870	100.00

* As disclosed in the Public Announcement

In terms of the Buyback Regulations, till May 3, 2023 the Company has already extinguished 8,58,579 (Eight Lakhs Fifty Eight Thousand Five Hundred and Seventy Nine) Equity shares bought back. The Company shall extinguish the balance of 25,88,716 (Twenty Five Lakhs Eighty Eight Thousand Seven Hundred and Sixteen) Equity shares aggregating 34,47,295 (Thirty Four Lakhs Forty Seven Thousand Two Hundred and Ninety Five) Equity shares bought back. The Post Buyback equity share capital is assuming extinguishment of all equity shares bought back by the Company until closure of the Buy-back.